Q1 Earnings Forecast for VIR Issued By Leerink Partnrs

Vir Biotechnology, Inc. (NASDAQ:VIR) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($1.09) per share for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.36) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s FY2025 earnings at ($3.80) EPS, FY2026 earnings at ($3.05) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($0.60) EPS.

VIR has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, January 10th. Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research report on Wednesday, November 20th. JPMorgan Chase & Co. upped their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. Barclays dropped their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Finally, Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.83.

Vir Biotechnology Trading Down 2.8 %

Shares of NASDAQ VIR opened at $10.23 on Wednesday. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -2.61 and a beta of 0.51. Vir Biotechnology has a one year low of $6.56 and a one year high of $14.45. The business has a fifty day simple moving average of $8.27 and a 200 day simple moving average of $8.37.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. During the same period in the prior year, the company posted ($1.22) earnings per share. Vir Biotechnology’s quarterly revenue was down 9.8% on a year-over-year basis.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in VIR. Blue Trust Inc. grew its holdings in Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares in the last quarter. Public Sector Pension Investment Board boosted its position in shares of Vir Biotechnology by 1.4% in the third quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company’s stock valued at $1,455,000 after acquiring an additional 2,600 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Vir Biotechnology by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 48,987 shares of the company’s stock valued at $436,000 after acquiring an additional 3,605 shares in the last quarter. Barclays PLC increased its position in Vir Biotechnology by 1.3% during the third quarter. Barclays PLC now owns 550,186 shares of the company’s stock worth $4,121,000 after acquiring an additional 7,287 shares during the period. Finally, Quest Partners LLC increased its position in Vir Biotechnology by 142.1% during the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock worth $113,000 after acquiring an additional 7,452 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. This represents a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 14,786 shares of company stock valued at $170,172 in the last quarter. 15.60% of the stock is currently owned by insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).